Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
63rd Annual Meeting of the Canadian Urological Association
Prostate Volume and PSA: Predictors of Disease Progression and Treatment Response in LUTS and BPH
Edmonton, Alberta / June 22-25, 2008
Edmonton - The proportion of men with lower urinary tract symptoms and benign prostatic hyperplasia is substantial and growing. Predicting which men will progress is important as it helps optimize treatment selection. Prostate volume and...
63rd Annual Meeting of the Canadian Urological Association
5-alpha Reductase Inhibitors in Prostate Cancer Prevention: The PCPT Revisited
Edmonton, Alberta / June 22-25, 2008
Edmonton - The PCPT (Prostate Cancer Prevention Trial) was a large independent randomized trial designed to answer whether long-term treatment with the 5-alpha reductase inhibitor (5ARI) finasteride could prevent prostate cancer in men ³55...
103rd Annual Meeting of the American Urological Association
Paradigm Shift in the Primary Prevention of Prostate Cancer: Reanalysis of the PCPT Data
Orlando, Florida / May 17-22, 2008
Orlando - Approximately 200,000 men are diagnosed with prostate cancer in the US annually and over 90% of them receive treatment for it. Reducing the frequency of diagnosed cancer could spare a substantial proportion the consequences of...
103rd Annual Meeting of the American Urological Association
Managing the Three Major Facets of Benign Prostatic Hyperplasia
Orlando, Florida / May 17-22, 2008
Orlando - The MTOPS study demonstrated that combination therapy significantly decreased the four-year incidence of disease progression in men with benign prostatic hyperplasia (BPH) compared with an a-blocker, a 5a-reductase inhibitor...
103rd Annual Meeting of the American Urological Association
Managing Urinary Frequency and Urgency in Patients with LUTS and OAB
Orlando, Florida / May 17-22, 2008
Orlando - The standard of care for men with lower urinary tract symptoms (LUTS) remains alpha-blockers but symptoms often co-exist with those of an overactive bladder (OAB), i.e. frequency and urgency, and in some men, OAB is the primary...
XXIIIrd Congress of the European Association of Urology
The Patient Perspective on Overactive Bladder: A Matter of Urgency
Milan, Italy / March 26-29, 2008
Milan - The principal symptom of an overactive bladder (OAB) is “urgency”—an overwhelming desire to urinate. Although this leads to a marked deterioration in quality of life and increased depression and anxiety, the subject is often treated...
XXIIIrd Annual Congress of the European Association of Urology
CombAT and Prostate Health: Combination Strategies for Long-term Efficacy
Milan, Italy / March 26-29, 2008
Milan - The combination of an alpha blocker to relieve symptoms and improve flow plus a 5a-reductase inhibitor (5ARI) to reduce prostate volume is a rational strategy for men with lower urinary tract symptoms secondary to benign prostatic...
6th World Congress on the Aging Male
The Role of 5-Alpha Reductase Inhibition in Prostate Cancer and BPH: Lessons From Clinical Trials
Tampa, Florida / February 21-24, 2008
Tampa - In the 1990s, widespread acceptance of the prostate-specific antigen (PSA) assay led to a sharp increase in the detection and subsequent treatment of prostate cancer. The advent of PSA testing coincided with the introduction of the...
Based on the following published article: Clinical Interventions in Aging 2007;2(4):1-10.
Clinical Impact of Age-related Testosterone Depletion and Therapy
The march of time brings about many alterations to the endocrine system, including a reduction in hypothalamic-pituitary-testicular function and a variable decrease in testosterone. Both total and bioavailable testosterone levels are...